We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$270M
AUM Growth
-$44.3M
Cap. Flow
-$68M
Cap. Flow %
-25.15%
Top 10 Hldgs %
74.66%
Holding
64
New
15
Increased
6
Reduced
6
Closed
18

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$10.4M
2
STAA icon
STAAR Surgical
STAA
+$9.86M
3
ICLR icon
Icon
ICLR
+$6.74M
4
NVAX icon
Novavax
NVAX
+$6M
5
HSKA
Heska Corp
HSKA
+$5.68M

Top Sells

Rank Stock Value
1
COR icon
Cencora
COR
+$31.3M
2
GSK icon
GSK
GSK
+$23.3M
3
SNY icon
Sanofi
SNY
+$13.6M
4
CNC icon
Centene
CNC
+$9.88M
5
SKIN icon
SkinHealth Systems
SKIN
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 59.82%
2 Financials 8.65%
3 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MODD icon
26
Modular Medical
MODD
$11M
$1.38M 0.51%
22,978
+3,833
+20% +$345K
MRUS
27
DELISTED
Merus
MRUS
$1.36M 0.5%
87,953
– –
SYRE icon
28
Spyre Therapeutics
SYRE
$9.11B
$1.35M 0.5%
120,198
-66,543
-36% -$1.2M
SVRA icon
29
Savara
SVRA
$1.13B
$1.34M 0.5%
866,448
+10,020
+1% +$13.7K
IDYA icon
30
IDEAYA Biosciences
IDYA
$3.55B
$1.27M 0.47%
70,000
– –
TYRA icon
31
Tyra Biosciences
TYRA
$1.78B
$1.16M 0.43%
152,159
– –
MBRX icon
32
Moleculin Biotech
MBRX
$2.87M
$1.1M 0.41%
2,765
– –
VNDA icon
33
Vanda Pharmaceuticals
VNDA
$319M
$1.01M 0.37%
136,325
-352,640
-72% -$3.43M
RLMD icon
34
PUT
Relmada Therapeutics
RLMD
$577M
$822K 0.3%
235,600
-370,600
-61% -$3.25M
RLMD icon
35
Relmada Therapeutics
RLMD
$577M
$822K 0.3%
+235,500
New +$2.07M
FUSN
36
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$820K 0.3%
260,448
– –
CNTB
37
Connect Biopharma Holdings
CNTB
$138M
$519K 0.19%
597,678
– –
SIEN
38
DELISTED
Sientra, Inc.
SIEN
$517K 0.19%
+255,000
New +$881K
ASLN
39
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$457K 0.17%
31,769
– –
ELEV
40
DELISTED
Elevation Oncology
ELEV
$342K 0.13%
359,731
– –
NXTC icon
41
NextCure
NXTC
$22.2M
$183K 0.07%
10,833
– –
CMAX
42
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
$119K 0.04%
1,452
+427
+42% +$63.8K
VINC
43
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$104K 0.04%
5,102
– –
NYXH
44
Nyxoah
NYXH
$143M
$80.4K 0.03%
16,110
– –
HUMA icon
45
Humacyte
HUMA
$194M
$20.3K 0.01%
+49,998
New +$152K
NGNE icon
46
Neurogene
NGNE
$709M
$19.5K 0.01%
1,916
– –
AFMD
47
DELISTED
Affimed
AFMD
– –
-82,107
Closed -$1.69M
ANIP icon
48
ANI Pharmaceuticals
ANIP
$1.84B
– –
-40,000
Closed -$1.29M
APLS
49
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-507,700
Closed -$34.7M
BHC icon
50
PUT
Bausch Health
BHC
$2.36B
– –
-281,200
Closed -$1.94M
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Sio Capital Management held 64 positions worth $270M, down 14% from $315M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Sio Capital Management withdrew a net $68M in Q4 2022, closing 18 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $23.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 64% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sio Capital Management opened a new position in Medtronic worth $9.95M.

  • Sio Capital Management's largest Q4 2022 buy was Medtronic: 128,000 shares worth $9.95M.
  • Sio Capital Management added most to United Therapeutics in Q4 2022, an estimated $2.52M increase.
  • Sio Capital Management's biggest Q4 2022 reduction was Cencora, cutting an estimated $31.3M.
  • Sio Capital Management fully exited GSK in Q4 2022, selling an estimated $23.3M.
  • Sio Capital Management's ten largest holdings make up 75% of its $270M portfolio in Q4 2022.
  • Sio Capital Management opened 15 new positions and closed 18 in Q4 2022.
  • Sio Capital Management's portfolio value fell 14% quarter-over-quarter to $270M.

Based on Sio Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.